TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study published in Nature Medicine links lower NRF2 levels in oligodendrocytes—the cells that maintain nerve-fiber insulation—to faster cognitive decline and abnormal myelin in older adults. Mouse experiments support a possible causal role, but whether drugs targeting the pathway can help prevent age-related decline in people remains unknown.
Researchers have linked reduced NRF2 activity in oligodendrocytes, brain cells that maintain the insulation around nerve fibers, to faster cognitive decline in older adults. The study, published in Nature Medicine, also found related abnormalities in human brain tissue and in mice, pointing to a possible biological pathway for future research—not a proven treatment for age-related memory loss.
The team, led by researchers from the University of Edinburgh and the UK Dementia Research Institute, studied participants in the Lothian Birth Cohort 1936. Their cognitive abilities had been tracked over many decades. Between ages 70 and 82, participants completed assessments of memory, processing speed and spatial reasoning. Of 1,091 people enrolled, 866 completed additional testing after age 70; most experienced some decline, but the pace differed.
In brain tissue collected after death from a subset of participants, greater decline over time was associated with fewer large nerve fibers and abnormal accumulation of myelin, the coating that helps electrical signals travel along those fibers. The tissue findings were associated with the rate of cognitive change, not simply how someone scored at one particular age. Researchers also found that people with more severe decline had lower NRF2 levels in oligodendrocytes. NRF2 helps regulate cellular defenses and normal function.
In mouse experiments, researchers reduced NRF2 specifically in oligodendrocytes. The mice developed excess myelin and lost large nerve fibers, changes resembling those seen in the human tissue. They also showed smaller improvements in cognitive performance as they aged. These experiments support a possible role for NRF2 loss in the observed changes, but they do not establish that the same process explains cognitive decline in all older adults.
A New Target in Aging Brain Research
The findings challenge the assumption that oligodendrocytes are always protective. These cells normally produce and maintain myelin, but the study suggests that age-related dysfunction may interfere with that role and potentially harm the nerve fibers they support. This shifts attention toward the condition of the brain’s insulation system, as well as the neurons it surrounds, when researchers investigate changes in memory and thinking.
The pathway may also be relevant to treatment research because medicines that act on NRF2 are already used for other neurological conditions, including multiple sclerosis. That creates a possible avenue for testing existing drugs, but it does not show that those medicines prevent or reverse cognitive decline in older people. Clinical research would need to establish whether a treatment is safe and effective for this purpose.
Veronique Miron, an MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital, part of Unity Health Toronto, said the team was encouraged because the work points to a potential strategy for preserving cognitive ability as populations age. Her statement describes the research’s promise; it is not evidence that a therapy is ready for patients.
As an affiliate, we earn on qualifying purchases.
From Cohort Records to Mouse Tests
The research draws on the Lothian Birth Cohort 1936, whose members have taken part in cognitive testing across much of their lives. Long-term records let researchers compare changes in cognition during older age rather than relying only on a single test result. The brain-tissue analysis, however, was possible only for a subset of participants whose tissue was examined after death.
The study combined those human observations with experiments in mice. The human data show an association between cognitive decline, myelin abnormalities and lower oligodendrocyte NRF2; they cannot by themselves establish which change came first or prove that NRF2 loss caused decline. The mouse manipulation offers evidence that changing NRF2 can produce related brain changes in that model, but findings in animals do not establish that a drug will have the same effects in people.
NRF2 is a cellular pathway already studied in other neurological settings. The report notes that medicines targeting it are used for conditions including multiple sclerosis and that prior studies have reported cognitive improvements in people with MS. Those results concern a different patient group and do not demonstrate benefit for age-related cognitive decline.
“We are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.”
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital
As an affiliate, we earn on qualifying purchases.
Treatment Benefits Remain Untested
The study does not show that lower NRF2 activity is the sole or primary cause of cognitive decline, or that restoring it would protect cognition in people. The human tissue findings are observational, and the animal experiments cannot establish how the pathway behaves across the diversity of human aging. The report also does not establish whether abnormal myelin is a cause, a consequence or part of a wider process involving other age-related brain changes.
No clinical trial in older adults is reported here to have tested an NRF2-targeting drug for age-related cognitive decline. Which medicine, dose, timing and patient group might be suitable—and whether benefits would outweigh risks—remain open questions. The study also does not indicate that the findings apply to every person with memory or thinking problems, which can have many causes.
oligodendrocyte support supplement
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Testing the Pathway in People
The next steps are to determine how NRF2 activity changes in oligodendrocytes during human aging and whether those changes reliably predict later cognitive outcomes. Researchers would also need to test whether altering the pathway can protect nerve fibers and cognition in further models before moving to appropriately designed clinical studies.
If a candidate drug is taken forward, trials would need to assess its safety and effects specifically in older adults with cognitive decline, rather than assume results from multiple sclerosis apply. Until such evidence is available, the findings identify a potential research target, not a treatment recommendation or a basis for changing prescribed medication.
cognitive decline prevention supplement
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What brain cells did the study investigate?
It focused on oligodendrocytes, cells that produce and maintain myelin, the coating around nerve fibers that helps signals travel through the brain.
What is NRF2, and what did researchers find?
NRF2 is a protein that regulates genes involved in cellular defenses and normal function. The study found lower NRF2 levels in oligodendrocytes in people with more severe cognitive decline; experiments reducing NRF2 in mice produced related nerve-fiber and myelin changes.
Does this mean an existing drug can prevent cognitive decline?
No. Medicines that act on the NRF2 pathway are used for other conditions, but this study did not test them as a treatment for age-related cognitive decline. Their safety and effectiveness for that purpose are unknown.
How strong is the evidence that NRF2 loss causes decline in people?
The human findings show an association, not proof of cause. The mouse experiments provide evidence that reducing oligodendrocyte NRF2 can produce similar changes in mice, but further research is needed to determine whether the pathway causes or contributes to decline in people.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
